Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy - Tabular View

Tracking Information
First Received Date ^ICMJE	July 16, 2002
Last Updated Date	June 23, 2005
Start Date ^ICMJE	January 2002
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00041795 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy
Official Title ^ICMJE	A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer
Brief Summary	This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Condition ^ICMJE	Peripheral Nervous System Diseases Chemotherapy-Induced Peripheral Neuropathy
Intervention ^ICMJE	Drug: leteprinim potassium (Neotrofin)
Study Arms / Comparison Groups
Publications *	Grundman M, Farlow M, Peavy G, Kim HT, Capparelli E, Schultz AN, Salmon DP, Ferris SH, Mobs R, Thomas RG, Schafer K, Campbell K, Hake AM, Schoos B, Thal LJ. A phase I study of AIT-082 in healthy elderly volunteers. J Mol Neurosci. 2002 Jun;18(3):283-93. Di Iorio P, Virgilio A, Giuliani P, Ballerini P, Vianale G, Middlemiss PJ, Rathbone MP, Ciccarelli R. AIT-082 is neuroprotective against kainate-induced neuronal injury in rats. Exp Neurol. 2001 Jun;169(2):392-9. Rathbone MP, Middlemiss PJ, Gysbers JW, Andrew C, Herman MA, Reed JK, Ciccarelli R, Di Iorio P, Caciagli F. Trophic effects of purines in neurons and glial cells. Prog Neurobiol. 1999 Dec;59(6):663-90. Review. Middlemiss PJ, Glasky AJ, Rathbone MP, Werstuik E, Hindley S, Gysbers J. AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. Neurosci Lett. 1995 Oct 20;199(2):131-4.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	50
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy. Sensory or motor neuropathy must be >/= grade 2 per Common Toxicity Criteria at baseline. In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable. Patient must have normal hematological cell counts. Patient must have a life expectancy of >/= 3 months.
Gender	Both
Ages	18 Years to 80 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00041795
Responsible Party
Study ID Numbers ^ICMJE	082-2001-005
Study Sponsor ^ICMJE	NeoTherapeutics
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	NeoTherapeutics
Verification Date	July 2002
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP